{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:37:18Z","timestamp":1769909838218,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.amjmed.2013.12.022","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T02:49:11Z","timestamp":1390963751000},"page":"519-529.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["\u2018Real-World\u2019 Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey"],"prefix":"10.1016","volume":"127","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Kalarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Popescu Mircea","family":"Ioachim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Tica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Cimaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Fragtrup","family":"Hellum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2013.12.022_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.recesp.2011.04.005","article-title":"The improved but unfinished business of stroke risk stratification in atrial fibrillation","volume":"64","author":"Banerjee","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib2","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on atrial fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2013.12.022_bib3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2013.12.022_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2013.12.022_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.amjmed.2013.12.022_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.20452\/pamw.1978","article-title":"Anticoagulation management in non-valvular atrial fibrillation: current and future directions","volume":"123","author":"Kornej","year":"2013","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.amjmed.2013.12.022_bib7","first-page":"190","article-title":"The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation","volume":"29","author":"Ogawa","year":"2013","journal-title":"J\u00a0Arrhythmia"},{"key":"10.1016\/j.amjmed.2013.12.022_bib8","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2013.12.022_bib9","first-page":"125","article-title":"Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib10","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib11","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","author":"Lip","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2013.12.022_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2013.12.022_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2013.12.022_bib14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archinte.158.12.1316","article-title":"Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials","volume":"158","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2013.12.022_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurjhf\/hfs005","article-title":"Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project","volume":"14","author":"Banerjee","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2013.12.022_bib16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jth.12177","article-title":"The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review","volume":"11","author":"Anandasundaram","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bmj.39351.706586.AD","article-title":"Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation","volume":"336","author":"Lip","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2013.12.022_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1160\/TH13-08-0677","article-title":"Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy","volume":"110","author":"Marin","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH13-04-0351","article-title":"Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation","volume":"110","author":"Bernard","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2013.12.022_bib21","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1160\/TH13-01-0054","article-title":"Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?","volume":"109","author":"Rold\u00e1n","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2013.12.022_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(99)00489-1","article-title":"Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators","volume":"35","author":"Hart","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2013.12.022_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2013.12.022_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","article-title":"A\u00a0randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)","volume":"36","author":"Rash","year":"2007","journal-title":"Age Ageing"},{"key":"10.1016\/j.amjmed.2013.12.022_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation","volume":"8","author":"Lip","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjmed.2013.12.022_bib29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-11-0768","article-title":"Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients","volume":"107","author":"Wilke","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2013European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2013.12.022_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jth.12140","article-title":"Recommendations for thromboprophylaxis in the 2012 focused update of the ESC Guidelines on Atrial Fibrillation: a commentary","volume":"11","author":"Lip","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2013.12.022_bib34","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2013.12.022_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1160\/TH12-08-0539","article-title":"Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey","volume":"109","author":"Pisters","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2013.12.022_bib37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:02:08Z","timestamp":1757581328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934314000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0002934314000692"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2013.12.022","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Real-World\u2019 Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2013.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}